Early post-exposure and curative therapeutic strategies against COVID-19
Copyright © 2023 SPLF. Published by Elsevier Masson SAS. All rights reserved..
INTRODUCTION: There now exist preventive and curative treatments available for both early and advanced stages of COVID-19 management.
CURRENT KNOWLEDGE: Antibiotics have no place in the initial therapeutic management of Sars-Cov-2 pneumonia. On the other hand, corticosteroids are recommended for patients requiring oxygen therapy≥2L/min. According to the latest recommendations, nirmatrelvir/ritonavir is indicated as an early treatment for adults not requiring oxygen therapy but at high risk of developing a severe form of COVID-19. In case of contraindication, remdesivir is an alternative therapy.
PERSPECTIVES: Although there is no indication for convalescent plasma outside of clinical trials, it seems promising for immunocompromised patients, particularly those with B lymphopenia. It is noteworthy that currently, with the predominance of the Omicron XBB.1.5 variant, monoclonal antibodies are no longer recommended as therapy except for sotrovimab, which still has partial efficacy and could be considered after expert opinion as salvage therapy in a previously well-established program.
CONCLUSION: Despite the evolution of variants, antivirals still appear to have activity and remain the first-line treatment for patients, in addition to vaccination.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
|---|---|
| Enthalten in: |
Revue des maladies respiratoires - 41(2024), 1 vom: 22. Jan., Seite 51-58 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Covid-19 : mise à jour des stratégies thérapeutiques curatives précoces et du patient sous oxygénothérapie |
|---|
| Beteiligte Personen: |
|---|
| Links: |
|---|
| Themen: |
Antibodies |
|---|
| Anmerkungen: |
Date Completed 22.01.2024 Date Revised 22.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.rmr.2023.10.007 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364846313 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364846313 | ||
| 003 | DE-627 | ||
| 005 | 20240122231938.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.1016/j.rmr.2023.10.007 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1267.xml |
| 035 | |a (DE-627)NLM364846313 | ||
| 035 | |a (NLM)37993363 | ||
| 035 | |a (PII)S0761-8425(23)00267-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Jaffal, K |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Early post-exposure and curative therapeutic strategies against COVID-19 |
| 246 | 3 | 3 | |a Covid-19 : mise à jour des stratégies thérapeutiques curatives précoces et du patient sous oxygénothérapie |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.01.2024 | ||
| 500 | |a Date Revised 22.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 SPLF. Published by Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a INTRODUCTION: There now exist preventive and curative treatments available for both early and advanced stages of COVID-19 management | ||
| 520 | |a CURRENT KNOWLEDGE: Antibiotics have no place in the initial therapeutic management of Sars-Cov-2 pneumonia. On the other hand, corticosteroids are recommended for patients requiring oxygen therapy≥2L/min. According to the latest recommendations, nirmatrelvir/ritonavir is indicated as an early treatment for adults not requiring oxygen therapy but at high risk of developing a severe form of COVID-19. In case of contraindication, remdesivir is an alternative therapy | ||
| 520 | |a PERSPECTIVES: Although there is no indication for convalescent plasma outside of clinical trials, it seems promising for immunocompromised patients, particularly those with B lymphopenia. It is noteworthy that currently, with the predominance of the Omicron XBB.1.5 variant, monoclonal antibodies are no longer recommended as therapy except for sotrovimab, which still has partial efficacy and could be considered after expert opinion as salvage therapy in a previously well-established program | ||
| 520 | |a CONCLUSION: Despite the evolution of variants, antivirals still appear to have activity and remain the first-line treatment for patients, in addition to vaccination | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Antibodies | |
| 650 | 4 | |a Anticorps | |
| 650 | 4 | |a Antiviral | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Nirmatrelvir | |
| 650 | 4 | |a Remdesivir | |
| 650 | 4 | |a Traitement | |
| 650 | 4 | |a Treatment | |
| 650 | 7 | |a Oxygen |2 NLM | |
| 650 | 7 | |a S88TT14065 |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 700 | 1 | |a Davido, B |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Revue des maladies respiratoires |d 1988 |g 41(2024), 1 vom: 22. Jan., Seite 51-58 |w (DE-627)NLM012622443 |x 1776-2588 |7 nnns |
| 773 | 1 | 8 | |g volume:41 |g year:2024 |g number:1 |g day:22 |g month:01 |g pages:51-58 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.rmr.2023.10.007 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 41 |j 2024 |e 1 |b 22 |c 01 |h 51-58 | ||